Sofosbuvir + Velpatasvir is approved to treat chronic hepatitis C in adults and children aged 6 years and older. It works against all major HCV genotypes and can be used with or without cirrhosis, including with ribavirin for decompensated cirrhosis. It provides a simple, once-daily treatment option.

Sofosbuvir + Velpatasvir works by blocking two key viral proteins needed for hepatitis C replication. Sofosbuvir inhibits the NS5B polymerase, while Velpatasvir blocks the NS5A protein, together stopping the virus from multiplying and helping clear the infection.

Sofosbuvir + Velpatasvir is administered orally as a once-daily tablet, with or without food. It is typically taken for a duration of 12 weeks, depending on the patient’s HCV genotype, liver disease status (with or without cirrhosis), and treatment history. In certain cases, such as patients with decompensated cirrhosis, it may be used in combination with ribavirin.

Sofosbuvir + Velpatasvir is usually well tolerated, with common side effects like headache, fatigue, and nausea. Less common effects include insomnia and diarrhea. When combined with ribavirin, anemia and rash may occur. Rarely, serious reactions or hepatitis B reactivation can happen, so monitoring is recommended.

Sofosbuvir + Velpatasvir should not be used in patients allergic to the drug or those taking medicines like rifampin or St. John’s Wort. Caution is needed in severe kidney disease and patients should be screened for hepatitis B before treatment. If used with ribavirin, there is a risk of birth defects and anemia, so strict contraception is required.

Sofosbuvir + Velpatasvir is a highly effective, once-daily treatment for chronic hepatitis C across all major genotypes. It works well in patients with or without cirrhosis and is approved for adults and children aged six and above. With good tolerability, few side effects, and short treatment duration, it marks an important advancement in HCV therapy.

Yes, it can be used in patients with decompensated cirrhosis (Child-Pugh B or C), but it is usually combined with ribavirin in these cases to enhance treatment efficacy.

Yes, it is a pan-genotypic regimen, meaning it is effective against all six major HCV genotypes (1–6), making it suitable for a broad range of patients.

Yes, Sofosbuvir + Velpatasvir has been shown to be safe and effective in HCV/HIV co-infected patients. However, potential drug interactions with antiretroviral therapy should be carefully managed.

Routine liver function tests, viral load (HCV RNA), and screening for hepatitis B virus (HBV) reactivation are recommended. Hemoglobin levels should also be monitored if ribavirin is co-administered.

No, the combination can be taken with or without food, as food does not significantly affect its absorption.

Caution is advised in patients with severe renal impairment or those on dialysis, as there is limited data on safety and efficacy in this population. Alternative regimens may be considered.

In case of treatment failure, retreatment strategies often include a combination of sofosbuvir, velpatasvir, and voxilaprevir or other alternative regimens based on resistance profiles.